APA (7th ed.) Citation

Quraishi, M. N., Cheesbrough, J., Rimmer, P., Mullish, B. H., Sharma, N., Efstathiou, E., . . . Cooney, R. (2025). Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures. Journal of Crohn's & Colitis, 19(2), 1. https://doi.org/10.1093/ecco-jcc/jjae189

Chicago Style (17th ed.) Citation

Quraishi, Mohammed Nabil, et al. "Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures." Journal of Crohn's & Colitis 19, no. 2 (2025): 1. https://doi.org/10.1093/ecco-jcc/jjae189.

MLA (9th ed.) Citation

Quraishi, Mohammed Nabil, et al. "Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures." Journal of Crohn's & Colitis, vol. 19, no. 2, 2025, p. 1, https://doi.org/10.1093/ecco-jcc/jjae189.